New Delhi. The IPO of Gujarat’s healthcare company Gujarat Kidney & Super Specialty has opened for investors from today. This public issue will remain open for subscription till December 24. This company, known as Kidney, runs a network of multispecialty hospitals and is now planning to expand by raising capital from the market. But the question is whether it would be right to invest money in this IPO?
Main information about Gujarat Kidney IPO
The price band of Gujarat Kidney IPO has been fixed at Rs 108 to Rs 114 per share. This entire issue is fresh, in which 2.20 crore new shares are being issued. The company wants to raise a total of Rs 250.80 crore through this IPO. This does not include OFS selling the stake of any promoter, that is, the entire money will go directly to the company.
Allotment, Listing and Lot Size
The allotment of the IPO is likely to take place on 26 December 2025. Successful investors can get shares on December 29, while the listing is expected on December 30 on BSE and NSE. The lot size of this IPO is 128 shares, which means retail investors will have to invest at least Rs 14,592.
Where will the money raised from IPO be used?
The company has made it clear that a major part of the money received from the IPO will be invested in expansion. About Rs 77 crore will be spent in the acquisition of Parekhs Hospital in Ahmedabad. Apart from this, Rs 12.40 crore will be given for the purchase of Ashwini Medical Centre. Rs 30.09 crore has been earmarked for the new hospital project in Vadodara, while investment will also be made in purchasing robotic medical equipment.
anchor investors’ confidence
Before the IPO, Gujarat Kidney has raised more than Rs 100 crore from anchor investors. The company allotted 87.73 lakh shares to anchor investors at a price of Rs 114 per share. Many foreign and domestic funds are involved in this, which indicates that institutional investors are interested in it.
GMP and subscription status
The GMP of Gujarat Kidney IPO in the gray market has been recorded at around Rs 3. That means the share can go up to around Rs 117 on listing. However, this premium is not considered very strong. Talking about subscription, there was a good response in the retail category on the first day, while the QIB segment remained sluggish.
Brokerage Opinion and Risk
Brokerage house Swastika Investmart has advised investors to be cautious. According to the report, the valuation of the company is at about 61 times P/E, which is much higher than other listed hospital companies. Being a small scale company, there is also a risk of delay in expansion and acquisition. In such a situation, it may be better for conservative and medium term investors to wait. Overall, Gujarat Kidney IPO is definitely an interesting opportunity in the healthcare sector, but high valuations and limited GMP do not make it a completely safe investment. Before investing, be sure to understand your risk and time frame.
(Disclaimer: The stocks mentioned here are for informational purposes only. If you want to invest money in any of these, then first consult a certified investment advisor. StuffUnknownwill not be responsible for any profit or loss of yours.)
